Blurbs

Analysts Are Bullish on Top Healthcare Stocks: Encompass Health (EHC), Intercept Pharma (ICPT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Encompass Health (EHCResearch Report), Intercept Pharma (ICPTResearch Report) and Veracyte (VCYTResearch Report) with bullish sentiments.

Encompass Health (EHC)

In a report released today, John Ransom from Raymond James maintained a Buy rating on Encompass Health, with a price target of $65.00. The company’s shares closed last Wednesday at $53.35.

According to TipRanks.com, Ransom is a 5-star analyst with an average return of 10.3% and a 59.3% success rate. Ransom covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, Tenet Healthcare, and HCA Healthcare.

Encompass Health has an analyst consensus of Strong Buy, with a price target consensus of $67.33, which is a 32.0% upside from current levels. In a report released yesterday, Deutsche Bank also maintained a Buy rating on the stock with a $62.00 price target.

See the top stocks recommended by analysts >>

Intercept Pharma (ICPT)

In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on Intercept Pharma, with a price target of $26.00. The company’s shares closed last Wednesday at $13.84.

According to TipRanks.com, Seedhouse is a 3-star analyst with an average return of 1.9% and a 40.9% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Galmed Pharmaceuticals, and Intellia Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intercept Pharma with a $26.13 average price target, implying a 107.1% upside from current levels. In a report issued on July 28, B.Riley Financial also maintained a Buy rating on the stock with a $30.00 price target.

Veracyte (VCYT)

Raymond James analyst Andrew Cooper maintained a Buy rating on Veracyte today and set a price target of $31.00. The company’s shares closed last Wednesday at $25.05.

According to TipRanks.com, Cooper is ranked 0 out of 5 stars with an average return of -21.4% and a 23.3% success rate. Cooper covers the Healthcare sector, focusing on stocks such as Exact Sciences, QuidelOrtho, and Haemonetics.

Veracyte has an analyst consensus of Strong Buy, with a price target consensus of $31.75, a 15.4% upside from current levels. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $31.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EHC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos